EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany

F B Rhold, J Hagemann, L Klimek, P Huber, M Gr Ger, A G Loth, B P Ernst, C Beutner, T Dombrowski, U F Rster-Ruhrmann, H Olze, M Cuevas und 6 weitere

Rhinology Journal · 2025

DOI: 10.4193/rhin25.104 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Rhinology Journal, 2025. Verfasst von F B Rhold und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Rhinology and Allergology, Wiesbaden, Germany;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Tübingen, Tü…. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Antibodies, Monoclonal, Humanized, Rhinitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Within the last years, monoclonal antibodies (biologicals) have revolutionized the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and significantly improved symptom control in otherwise refractory cases. The effectiveness of the biological mepolizumab, an IL-5 receptor antibody, has not yet been investigated extensively. This multi-centric study assesses its impact on a large German patient cohort including biological naïve and switched patients. Methodology: In this retrospective multi-centric study, patients with the diagnosis of severe CRSwNP treated with mepolizumab by German tertiary referral centers were included. Data were collected retrospectively from patient records. The change from baseline regarding patient reported symptom control, serum biomarkers, nasal polyp score (NPS), and sense of smell were analysed over a course of up to 30 months.

Results

96 patients from 8 tertiary treatment centers were included, 36.5% female, with a mean age of 54.1±14.3 years. Patient reported outcome measures, smell, and NPS improved significantly within 6 months after treatment initiation or switch from a different biological to mepolizumab. Change from baseline in outcome parameters was smaller in the switch-group, whereas comorbid asthma indicated greater treatment success.

Conclusions

Our real-world data show a sustained therapeutic effect of mepolizumab in CRSwNP, including a large proportion of patients who were previously treated with a different biological. This study is the largest real-world cohort to date depicting realistic treatment and disease situations, confirming a broad range of indication for mepolizumab in severe CRSwNP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsSinusitisAntibodies, Monoclonal, HumanizedRhinitisHumansFemaleMaleMiddle AgedChronic DiseaseRetrospective StudiesGermanyTreatment OutcomeAdultAgedRhinosinusitis

Substanzen

mepolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Center for Rhinology and Allergology, Wiesbaden, Germany;Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Tübingen, Tübingen, Germany.
  • Center for Rhinology and Allergology, Wiesbaden, Germany.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig Maximilian University of Munich, Munich, Germany.
  • Department of Otorhinolaryngology, Goethe University Frankfurt, University Medical Center, Frankfurt am Main, Germany.
  • Department of Dermatology, Venereology and Allergology, University Medical Center G?ttingen, G?ttingen, Germany.
  • Department of Otolaryngology, Head and Neck Surgery, University Medical Center Georg-August-University, G?ttingen, Germany.

Zitieren

APA

B Rhold, F., Hagemann, J., Klimek, L., Huber, P., Gr Ger, M., Loth, A. G., Ernst, B. P., Beutner, C., Dombrowski, T., F Rster-Ruhrmann, U., Olze, H., Cuevas, M., Gunder, N., Malanda, J., Laudien, M., Albrecht, T., Matthias, C., & Becker, S. (2025). Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany. Rhinology Journal. https://doi.org/10.4193/rhin25.104

Vancouver

B Rhold F, Hagemann J, Klimek L, Huber P, Gr Ger M, Loth AG, et al. Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany. Rhinology Journal. 2025. doi:10.4193/rhin25.104

BibTeX
@article{BRhold2025,
  author = {B Rhold, F and Hagemann, J and Klimek, L and Huber, P and Gr Ger, M and Loth, A G and Ernst, B P and Beutner, C and Dombrowski, T and F Rster-Ruhrmann, U and Olze, H and Cuevas, M and Gunder, N and Malanda, J and Laudien, M and Albrecht, T and Matthias, C and Becker, S},
  title = {Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany},
  journal = {Rhinology Journal},
  year = {2025},
  doi = {10.4193/rhin25.104}
}
Kostenlos starten →